 This study is a phase II randomized multicenter study. Patients will be enrolled at time of diagnosis and will receive one or two cycles of induction chemotherapy. Patients, without indication of intensification by allogeneic stem cell transplantation andor without HLA Human Leukocyte Antigen-compatible donor, who attain a CR after one or two cycles of induction chemotherapy, will be eligible for the study Clofarabine Intermediate-Dose Cytarabine CLARAversus High-Dose Cytarabine HDACand will be randomized between 3 courses of CLARA chemotherapy and 3 courses of HDAC chemotherapy as consolidation. 